Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia

Circulation

Volumn 118, Issue 4, 2008, Pages 410-421

  Finley IV, John J ^a   Konstam, Marvin A ^a   Udelson, James E ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

Heart failure; Hormones; Kidney; Receptors

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CONIVAPTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; LIXIVAPTAN; LOOP DIURETIC AGENT; MOZAVAPTAN; SATAVAPTAN; SODIUM; SPIRONOLACTONE; TOLVAPTAN; VASOPRESSIN; VASOPRESSIN ANTAGONIST; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V1B RECEPTOR; VASOPRESSIN V2 RECEPTOR; VASOPRESSIN V3 RECEPTOR; ARGIPRESSIN; VASOPRESSIN DERIVATIVE; VASOPRESSIN RECEPTOR;

ABSENCE OF SIDE EFFECTS; ASCITES; BINDING AFFINITY; CLINICAL TRIAL; CYTOLOGY; DEHYDRATION; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG WITHDRAWAL; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEMODYNAMICS; HUMAN; HYPOKALEMIA; HYPONATREMIA; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; LOADING DRUG DOSE; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SODIUM BLOOD LEVEL; STROKE; THIRST; UNSPECIFIED SIDE EFFECT; VASOPRESSIN RELEASE; XEROSTOMIA; DRUG ANTAGONISM; PHYSIOLOGY;

ARGININE VASOPRESSIN; HEART FAILURE; HUMANS; HYPONATREMIA; RECEPTORS, VASOPRESSIN; VASOPRESSINS;

EID: 49149119580     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.108.765289     Document Type: Review

References (71)

1. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N EnglJ Med. 1999;341:577-585.
2. Thibonnier M. Vasopressin receptor antagonists in heart failure. Curr Opin Pharmacol. 2003;3:683-687.
3. Penit J, Faure M, Jard S. Vasopressin and angiotensin II receptors in rat aortic smooth muscle cells in culture. Am J Physiol. 1983;244:E72-E82.
4. Lee CR, Watkins ML, Patterson JH, Gattis W, O'connor CM, Gheo- rghiade M, Adams KF Jr. Vasopressin: a new target for the treatment of heart failure. Am Heart J. 2003;146:9-18.
5. Bankir L. Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects. Cardiovasc Res. 2001;51:372-390.
6. Ganong WF. Review of Medical Physiology. 10th ed. Los Altos, Calif: Lange Medical Publications; 1981.
7. Carmichael MC, Kumar R. Molecular biology of vasopressin receptors. Semin Nephrol. 1994;14:341-348.
8. Jackson EK. Vasopressin and other agents affecting the renal conservation of water. In: Goodman LS, Gilman A, Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman's the Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw-Hill; 2006:2021.
9. Nielsen S, Chou CL, Marples D, Christensen EI, Kishore BK, Knepper MA. Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane. Proc Natl Acad Sci USA. 1995;92:1013-1017.
10. Kalra PR, Anker SD, Coats AJ. Water and sodium regulation in chronic heart failure: the role of natriuretic peptides and vasopressin. Cardiovasc Res. 2001;51:495-509.
11. Uretsky BF, Verbalis JG, Generalovich T, Valdes A, Reddy PS. Plasma vasopressin response to osmotic and hemodynamic stimuli in heart failure. Am J Physiol. 1985;248:H396-H402.
12. Goldsmith SR, Francis GS, Cowley AW Jr, Levine TB, Cohn JN. Increased plasma arginine vasopressin levels in patients with congestiveheart failure. J Am Coll Cardiol. 1983;1:1385-1390.
13. Szatalowicz VL, Arnold PE, Chaimovitz C, Bichet D, Berl T, Schrier RW. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med. 1981;305:263-266.
14. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, Kubo SH, Rudin-Toretsky E, Yusuf S. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82:1724-1729.
15. Kramer BK, Schweda F, Riegger GA. Diuretic treatment and diuretic resistance in heart failure. Am J Med. 1999;106:90-96.
16. Creager MA, Faxon DP, Cutler SS, Kohlmann O, Ryan TJ, Gavras H. Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: comparison with the renin-angiotensin system and the sympathetic nervous system. J Am Coll Cardiol. 1986;7:758-765.
17. Nicod P, Waeber B, Bussien JP, Goy JJ, Turini G, Nussberger J, Hofbauer KG, Brunner HR. Acute hemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failure.Am J Cardiol. 1985;55:1043-1047.
18. Pruszczynski W, Vahanian A, Ardaillou R, Acar J. Role of antidiuretic hormone in impaired water excretion of patients with congestive heart failure. J Clin Endocrinol Metab. 1984;58:599-605.
19. Goldsmith SR, Francis GS, Levine TB, Cowley AW Jr, Cohn JN. Impaired response of plasma vasopressin to orthostatic stress in patients with congestive heart failure. J Am Coll Cardiol. 1983;2:1080-1083.
20. Rouleau JL, de Champlain J, Klein M, Bichet D, Moye L, Packer M, Dagenais GR, Sussex B, Arnold JM, Sestier F. Activation of neuro- humoral systems in postinfarction left ventricular dysfunction. J Am Coll Cardiol. 1993;22:390-398.
21. Gavras H, Ribeiro AB, Kohlmann O, Saragoca M, Mulinari RA, Ramos 0, Gavras I. Effects of a specific inhibitor of the vascular action of vasopressin in humans. Hypertension. 1984;6(suppl):I-156-I-60.
22. Udelson JE, Smith WB, Hendrix GH, Painchaud CA, Ghazzi M, Thomas 1, Ghali JK, Selaru P, Chanoine F, Pressler ML, Konstam MA. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation.2001;104:2417-2423.
23. Udelson JE, McGrew FA, Flores E, Ibrahim H, Katz S, Koshkarian G, O'Brien T, Kronenberg MW, Zimmer C, Orlandi C, Konstam MA. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol. 2007;49:2151-2159.
24. Goldsmith SR. Vasopressin as vasopressor. Am J Med. 1987;82:1213-1219.
25. Goldsmith SR, Francis GS, Cowley AW Jr, Goldenberg IF, Cohn JN. Hemodynamic effects of infused arginine vasopressin in congestive heart failure. J Am Coll Cardiol. 1986;8:779-783.
26. Monos E, Cox RH, Peterson LH. Direct effect of physiological doses of arginine vasopressin on the arterial wall in vivo. Am J Physiol. 1978;234:H167-H172.
27. Naitoh M, Suzuki H, Murakami M, Matsumoto A, Arakawa K, Ichihara A, Nakamoto H, Oka K, Yamamura Y, Saruta T. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am J Physiol. 1994;267:H2245-H2254.
28. Clair MJ, King MK, Goldberg AT, Hendrick JW, Nisato R, Gay DM,Morrison AE, McElmurray JH 3rd, Krombach RS, Bond BR, Cazaubon C, Nisato D, Spinale FG. Selective vasopressin, angiotensin II, or dual receptor blockade with developing congestive heart failure. J Pharmacol Exp Ther. 2000;293:852-860.
29. Nakamura Y, Haneda T, Osaki J, Miyata S, Kikuchi K. Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V(1A) receptor. Eur J Pharmacol. 2000;391:39-48.
30. Tahara A, Tomura Y, Wada K, Kusayama T, Tsukada J, Ishii N, Yatsu T, Uchida W, Tanaka A. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced hyperplasia and hypertrophy of
31. cultured vascular smooth-muscle cells. J Cardiovasc Pharmacol. 1997;30:759-766.
32. Fukuzawa J, Haneda T, Kikuchi K. Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V1 receptor. Mol Cell Biochem. 1999;195:93-98.
33. Xu DL, Martin PY, Ohara M, St John J, Pattison T, Meng X, Morris K, Kim JK, Schrier RW. Upregulation of aquaporin-2 water channel expression in chronic heart failure rat. JClin Invest. 1997;99:1500-1505.
34. Chan PS, Coupet J, Park HC, Lai F, Hartupee D, Cervoni P, Dusza JP, Albright JD, Ru X, Mazandarani H, Tanikella T, Shepherd C, Ochalski L, Bailey T, Lock TY, Ning X, Taylor JR, Spinelli W. VPA-985, a non-peptide orally active and selective vasopressin V2 receptor antagonist. In: Zingg HH, Bourque CW, Bichet DG, eds. Vasopressin and Oxytocin: Molecular, Cellular, and Clinical Advances. New York, NY: Plenum; 1998;449:439-443. Advances in Experimental Medicine and Biology series.
35. Abraham WT, Shamshirsaz AA, McFann K, Oren RM, Schrier RW. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol. 2006;47:1615-1621.
36. Udelson JE, Orlandi C, Ouyang J, Krasa H, Zimmer CA, Frivold G, Haught WH, Meymandi S, Wedge P, Konstam MA, Gheorghiade M. Acute hemodynamic effects of tolvaptan, a vasopressin V-2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: the ECLIPSE international, multicenter, randomized placebo-controlled trial. J Card Fail. 13:793-794.
37. Martin PY, Abraham WT, Lieming X, Olson BR, Oren RM, Ohara M,Schrier RW. Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure. JAmSoc Nephrol. 1999;10:2165-2170.
38. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C, SALT I. Tolvaptan, a selective oral vasopressin V2- receptorantagonist, for hyponatremia. N Engl J Med. 2006;355:2099-2112.
39. Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, Orlandi C, Tolvaptan I. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double- blind, randomized trial. Circulation. 2003;107:2690-2696.
40. Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N, for the Conivaptan Study Group. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am JNephrol. 2007;27:447-457.
41. Wong F, Blei AT, Blendis LM, Thuluvath PJ. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology. 2003;37:182-191.
42. Soupart A, Gross P, Legros JJ, Alfoldi S, Annane D, Heshmati HM, Decaux G. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with SR 121 463 B, an orally active, nonpeptide, vasopressin V-2 receptor antagonist. JAmSoc Nephrol. 2006;11:634-640.
43. Nakamura S, Shuji I, Hiroyuki F, Yoshitaka Y, Toyoki M. Binding affinities of mozavaptan hydrochloride (OPC-31260) for vasopressin receptors. Jpn Pharmacol Ther. 2006;34:827-834.
44. Shigeki N, Hiroyuki H, Shiro T, Toshiyuki O, Toshiki M, Yoshitaka Y, Toyoki M. Aquaretic effects of mozavaptan hydrochloride (OPC-31260) in conscious rats and dogs. Jpn Pharmacol Ther. 2006;34:835-845.
45. Verbalis J, Bisaha J, Smith N. Novel vasopressin V1A and V2 antagonist (conivaptan) increases serum sodium concentration and effective water clearance in patients with hyponatremia. J Card Fail. 2004;10:S27. Abstract.
46. Naitoh M, Risvanis J, Balding LC, Johnston CI, Burrell LM. Neuro- hormonal antagonism in heart failure: beneficial effects of vasopressin V(1a) and V(2) receptor blockade and ACE inhibition. Cardiovasc Res.2002;54:51-57.
47. Hirano T, Yamamura Y, Nakamura S, Onogawa T, Mori T. Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther. 2000;292:288-294.
48. Yamamura Y, Nakamura S, Itoh S, Hirano T, Onogawa T, Yamashita T, Yamada Y, Tsujimae K, Aoyama M, Kotosai K, Ogawa H, Yamashita H, Kondo K, Tominaga M, Tsujimoto G, Mori T. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998;287:860-867.
49. Gines P, Wong F, Watson H, Milutinovic S, Ruiz del Arbol L, Olteanu D. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology. February 21, 2008. DOI: 10.1002/hep.22293. Available at: http://www3.interscience.wiley.com/journal. Accessed April 13, 2008.
50. Gheorghiade M, Gottlieb SS, Udelson JE, Konstam MA, Czerwiec F, Ouyang J, Orlandi C, Tolvaptan I. Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia.Am J Cardiol. 2006;97:1064-1067.
51. Gheorghiade M, Abraham WT, Albert NM, Gattis Stough W, Greenberg BH, O'Connor CM, She L, Yancy CW, Young J, Fonarow GC, for the OPTIMIZE-HF Investigators and Coordinators. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J. 2007;28:980-988.
52. Klein L, O'Connor CM, Leimberger JD, GattisStough W, Pina IL, Felker GM, Adams KFJ, Califf RM, Gheorghiade M, for the OPTIMECHF Investigators. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Mil- rinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Study. Circulation. 2005;111:2454 -2460.
53. Gheorghiade M, Rossi JS, Cotts W, Shin DD, Hellkamp AS, Pina IL,Fonarow GC, DeMarco T, Pauly DF, Rogers J, DiSalvo TG, Butler J, Hare JM, Francis GS, Stough WG, O'Connor CM. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial. Arch Intern Med. 2007;167:1998-2005.
54. Gheorghiade M, Gattis WA, O'Connor CM, Adams KF, Elkayam U, Barbagelata A, Ghali JK, Benza RL, McGrew FA, Klapholz M. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291:1963-1971.
55. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297:1319-1331.
56. THE BALANCE Study: treatment of hyponatremia based on lixivaptan in NYHA class III/IV cardiac patient evaluation. Available at: http:// www.clinicaltrials.gov/ct2/show/NCT005786957term = lixivaptan& rank=1. Accessed May 12,2008.
57. Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C, for the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007;297:1332-1343.
58. Gheorghiade M, Orlandi C, Burnett JC, Demets D, Grinfeld L, Maggioni A, Swedberg K, Udelson JE, Zannad F, Zimmer C, Konstam MA. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study With Tolvaptan (EVEREST). J Card Fail. 2005;11:260-269.
59. Goldsmith S. Efficacy and safety of conivaptan in acute decompensated heart failure; a dose-ranging pilot study. J Card Fail. 2006;12(suppl):S72. Abstract.
60. Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531-1540.
61. Russell SD, Adams KF, Shaw JP, Gattis WA, O'Connor CM. Results of a twelve week double-blind, placebo-controlled, multicenter study of oral conivaptan to assess functional capacity in patients with class III chronic heart failure. J Card Fail. 2003;9:S60-S60.
62. Udelson JE, Orlandi C, O'Brien T, Sequeira R, Ouyang J, Konstam MA. Vasopressin receptor blockade in patients with congestive heart failure: results from a placebo controlled, randomized study comparing the effects of tolvaptan, furosemide, and their combination. J Am Coll Cardiol.2002;39:156. Abstract.
63. Costello-Boerrigter LC, Smith WB, Boerrigter G, Ouyang J, ZimmerCA, Orlandi C, Burnett JC Jr. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol.2006;290: F273-F278.
64. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure.J Am Coll Cardiol. 2005;46:1785-1791.
65. Forman DE, Butler J, Wang Y, Abraham WT, O'Connor CM, Gottlieb SS, Loh E, Massie BM, Rich MW, Stevenson LW. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004;43:61-67.
66. De Luca L, Klein L, Udelson JE, Orlandi C, Sardella G, Fedele F, Gheorghiade M. Hyponatremia in patients with heart failure.Am J Cardiol. 2005;96:19L-23L.
67. 'TEMPO 3/4 Trial' Tolvaptan Efficacy and Safety in Management of Polycystic Kidney Disease and Its Outcomes (TEMPO3/4). Available at: ttp://www.clinicaltrials.gov/ct2/show/NCT004289487term=TEMPO& rank= 1. Accessed February 28, 2008.
68. Hunt SA, American College of Cardiology, American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). American College of Cardiology Web Site. J Am Coll Cardiol. 2005;46:e1-e82.
69. McMurray JJ, Teerlink JR, Cotter G, Bourge RC, Cleland JG, Jondeau G,Krum H, Metra M, O'Connor CM, Parker JD, Torre-Amione G, van Veldhuisen DJ, Lewsey J, Frey A, Rainisio M, Kobrin I, for the VERITAS Investigators. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA. 2007;298:2009-2019.
70. Mann DL, McMurray JJ, Packer M. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109:1594 -1602.
71. Ghali JK, Koren MJ, Taylor JR, Brooks-Asplund E, Fan K, Long LA,Smith N. Efficacy and safety of oral conivaptan: a V1a/V2 vasopressin receptor antagonist assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endo- crinolMetab. 2006;91:2145-2152.